MAP2K7 and Papillary Craniopharyngioma: Almost all studies included case reports, with the exception of one study which was a case-series investigating the use of BRAF/MEK inhibitors as neoadjuvant treatment in 16 patients with papillary craniopharyngioma [18] and one cohort study composed of 16 patients using BRAFi as neoadjuvant, adjuvant, or palliative strategy [20].